N-Acetyl-3-(2-naphthyl)-DL-alanin | 37439-99-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Acetyl-3-(2-naphthyl)-DL-alanin
• 英文别名: N-Acetyl-3-(2-naphthyl)-DL-alanine；2-acetamido-3-naphthalen-2-ylpropanoic acid
• CAS: 37439-99-9；37440-01-0；58438-02-1
• 化学式: C₁₅H₁₅NO₃
• mdl: MFCD01076160
• 分子量: 257.289
• InChiKey: HGTIILKZSFKZMS-UHFFFAOYSA-N

物化性质

• 熔点：
  185-186
• 沸点：
  543.4±43.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  遵循规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2924299090
• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362+P364
• 危险性描述：
  H315,H319
• 储存条件：
  存放于2-8℃阴凉干燥处

SDS

Name:	(R)-N-Acetyl-2-naphthylalanine 95% (98% E.E.) Material Safety Data Sheet
Synonym:	N-Acetyl-D-2-naphthylalanine
CAS:	37440-01-0

Section 1 - Chemical Product MSDS Name:(R)-N-Acetyl-2-naphthylalanine 95% (98% E.E.) Material Safety Data Sheet
Synonym:N-Acetyl-D-2-naphthylalanine

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
37440-01-0	(R)-N-Acetyl-2-naphthylalanine	95%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 37440-01-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: off-white to light beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H15NO3
Molecular Weight: 257.28

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 37440-01-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(R)-N-Acetyl-2-naphthylalanine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 37440-01-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 37440-01-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 37440-01-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-Acetyl-3-(2-naphthyl)-DL-alanin 在 chloropyridinecobaloxime(III) 、 9-mesityl-2,7-dimethyl-10-phenylacridin-10-ium tetrafluoroborate 、 三乙酰氧基硼氢化钠 、 sodium carbonate 作用下， 以 甲醇 、 水 为溶剂， 反应 16.0h， 以80%的产率得到
  参考文献：
  名称：

  的脱羧消除Ñ经由Photoredox /钴双催化酰基氨基酸

  摘要：

  已经实现了直接从容易获得且廉价的氨基酸直接合成烯酰胺和烯氨基甲酸酯的双重催化策略。这种温和而有效的方案利用有机光氧化还原催化剂和钴氧肟催化剂来实现脱羧消除，利用氢的释放来驱动氧化。因此，该反应在没有化学计量的氧化剂或先前试图实现类似消除的强迫条件下发生。

  DOI：

  10.1021/acscatal.8b03282
• 作为产物：
  描述：

  acetylamino-[2]naphthylmethyl-malonic acid diethyl ester 在 sodium hydroxide 、 水 作用下， 以 乙醇 为溶剂， 反应 29.0h， 以2.15 g的产率得到N-Acetyl-3-(2-naphthyl)-DL-alanin
  参考文献：
  名称：

  对映选择性达金-韦斯特反应

  摘要：

  在这里，我们报道了第一个对映选择性达金-韦斯特反应的进展，该反应可产生ee高达58％ee的α-乙酰氨基甲基酮，并具有良好的收率。将获得的两种产品重结晶一次，以达到84％ee。所使用的含甲基咪唑的寡肽既催化the内酯中间体的乙酰化反应，又催化末端对映选择性脱羧质子化反应。我们提出了一种分散控制的反应路径，该路径确定了脱羧后中间烯醇化物的不对称质子化。

  DOI：

  10.1002/anie.201509863

文献信息

• Photoredox/Cobalt Dual‐Catalyzed Decarboxylative Elimination of Carboxylic Acids: Development and Mechanistic Insight
  作者：Kaitie C. Cartwright、Ebbin Joseph、Chelsea G. Comadoll、Jon A. Tunge

  DOI：10.1002/chem.202001952

  日期：2020.9.25

  Recently, dual‐catalytic strategies towards the decarboxylative elimination of carboxylic acids have gained attention. Our lab previously reported a photoredox/cobaloxime dual catalytic method that allows the synthesis of enamides and enecarbamates directly from N‐acyl amino acids and avoids the use of any stoichiometric reagents. Further development, detailed herein, has improved upon this transformation's

  近来，用于羧酸脱羧消除的双重催化策略已引起关注。我们的实验室以前曾报道过光氧化还原/钴肟双催化方法，该方法可直接从N酰基氨基酸合成酰胺和烯甲酸酯，并避免使用任何化学计量试剂。本文详述的进一步开发改进了这种转化的用途，进一步的实验为反应机理提供了新的见解。这些新的发展和见识有望帮助扩大光氧化还原/钴双催化系统。
• Convenient Method for Reduction of C-N Double Bonds in Oximes, Imines, and Hydrazones Using Sodium Borohydride–Raney Ni System
  作者：Yihua Yang、Shouxin Liu、Junzhang Li、Xia Tian、Xiaoli Zhen、Jianrong Han

  DOI：10.1080/00397911.2011.562063

  日期：2012.9

  Abstract A practical method has been developed for reduction of C-N double bond in oximes, imines, and hydrazones with sodium borohydride catalyzed by Raney Ni. The reactions were carried out in basic aqueous solution, and the desired products were obtained in moderate yields after a simple procedure. This method can be applied to synthesize simpler aliphatic or aromatic amines and its analogs. GRAPHICAL

  摘要 开发了一种在 Raney Ni 催化下用硼氢化钠还原肟、亚胺和腙中 CN 双键的实用方法。反应在碱性水溶液中进行，经过简单的程序，以中等收率得到所需产物。该方法可用于合成更简单的脂肪族或芳香族胺及其类似物。图形概要
• Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone, their preparation and pharmaceutical compositions containing them
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0021234A1

  公开（公告）日：1981-01-07

  Nonapeptide and decapeptide analogs of LH-RH of the formula (pyro)Glu-His-V-Ser-W-X-Y-Arg-Pro-Z (I) and the pharmaceutically acceptable salt thereof wherein: V is tryptophyl, phenylalanyl or 3-(1-naphthyl)-L-alanyl; W is tyrosyl, phenylalanyl or 3-(1-pentafluorophenyl)-L-alanyl; X is a D-amino acid residue wherein R is (a) a carbocyclic aryl-containing radical selected from the group consisting of naphthyl, anthryl, fluorenyl, phenanthryl, biphenylyl, benzhydryl and phenyl substituted with three or more straight chain lower alkyl groups; or (b) a saturated carbocyclic radical selected from the group consisting of cyclohexyl substituted with three or more straight chain lower alkyl groups, perhydronaphthyl, perhydrobiphenylyl, perhydro-2,2-diphenylmethyl and adamantyl; Y is leucyl, isoleucyl, nor-leucyl or N-methyl-leucyl; Z is glycinamide or-NH-R1, wherein R' is lower alkyl, cycloalkyl, fluoro lower alkyl or wherein R2 is hydrogen or lower alkyl, are disclosed. These compounds exhibit potent LH-RH agonist properties.

  式中的 LH-RH 的非肽和十肽类似物 (焦)Glu-His-V-Ser-W-X-Y-Arg-Pro-Z (I)及其药学上可接受的盐 其中： V 是色氨酰、苯丙氨酰或 3-(1-萘基)-L-丙氨酰； W 是酪氨酰基、苯丙氨酰基或 3-(1-五氟苯基)-L-丙氨酰； X 是 D-氨基酸残基，其中 R 是 (a) 一个含碳环芳基，选自由萘基、蒽基、芴基、菲基、联苯基、苯hydryl 和被三个或三个以上直链低级烷基取代的苯基组成的组；或 (b) 饱和碳环基，选自由三个或三个以上直链低级烷基取代的环己基、全氢萘 基、全氢联苯基、全氢-2,2-二苯基甲基和金刚烷基组成的组； Y 是亮氨酰、异亮氨酰、去亮氨酰或 N-甲基亮氨酰； Z 是甘氨酰胺或-NH-R1，其中 R' 是低级烷基、环烷基、氟低级烷基或 其中 R2 是氢或低级烷基。这些化合物具有强效的 LH-RH 激动剂特性。
• Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists, methods of making them, and their pharmaceutical uses
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0049628A2

  公开（公告）日：1982-04-14

  Nonapeptide and decapeptide analogs of LHRH which have the formula and the pharmaceutically acceptable salts thereof, wherein: X is a D-alanyl residue wherein one hydrogen on C-3 is replaced by: a) a carbocyclic aryl-containing radical selected from the group consisting of phenyl substituted with three or more straight chain lower alkyl groups, naphthyl, anthryl, fluorenyl, phenanthryl, biphenylyl and benzhydryl; or b) a saturated carbocyclic radical selected from the group consisting of cyclohexyl substituted with three or more straight chain lower alkyl groups, perhydronaphthyl, perhydrobiphenylyl, perhydro-2,2-diphenylmethyl, and adamantyl; or c) a heterocyclic aryl containing radical selected from the group consisting of radicals represented by the following structural formulas: wherein A" and A' are independently selected from the group consisting of hydrogen, lower alkyl, chlorine, and bromine, and G is selected from the group consisting of oxygen, nitrogen, and sulfur; A is an aminoacyl residue selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, N-acyl-L-prolyl, N-acyl-D-prolyl, N-acyl-D-tryptophanyl, N-acyl-D-phenylalanyl, N-acyl-D-p-halophenylalanyl, and N-acyl-X wherein X is as defined previously; B is an amino acyl residue selected from the group consisting of D-phenylalanyl, D-p-halophenylalanyl, 2,2-diphenylglycyl, and X wherein X is as defined previously; C is an amino acyl residue selected from the group consisting of L-tryptophanyl, D-tryptophanyl, D-phenylalanyl and X wherein X is as defined above; E is glycinamide or -NH-R1, wherein R1 is lower alkyl, cycloalkyl, fluoro lower alkyl or R2 is hydrogen or lower alkyl; are disclosed. These compounds are LHRH antagonists.

  LHRH 的非肽和十肽类似物，其分子式为 及其药学上可接受的盐类，其中 X是D-丙氨酰残基，其中C-3上的一个氢被下列物质取代 a) 一个含碳环芳基，选自由三个或三个以上直链低级烷基取代的苯基、萘基、蒽基、芴基、菲基、联苯基和二苯基组成的组；或 b) 饱和碳环基，选自由三个或三个以上直链低级烷基取代的环己基、过氢萘基、过氢联苯基、过氢-2,2-二苯基甲基和金刚烷基组成的组；或 c) 杂环芳基，选自由下列结构式所代表的基团组成的组： 其中 A "和 A'独立地选自氢、低级烷基、氯和溴组成的组，G 选自氧、氮和硫组成的组； A 是氨基酰基残基，选自由 L-焦谷氨酰、D-焦谷氨酰、N-酰基-L-脯氨酰、N-酰基-D-脯氨酰、N-酰基-D-色氨酰、N-酰基-D-苯丙氨酰、N-酰基-D-对卤苯丙氨酰和 N-酰基-X 所组成的组，其中 X 如前定义； B 是选自 D-苯丙氨酰、D-对卤代苯丙氨酰、2,2-二苯基甘氨酰和 X 所组成的组的氨基酰基残基，其中 X 如前所定义； C 是氨基酰基残基，选自由 L-色氨酰、D-色氨酰、D-苯丙氨酰和 X 所组成的组，其中 X 如前所定义； E 是甘氨酰胺或-NH-R1，其中 R1 是低级烷基、环烷基、氟低级烷基或-NH-R1。 R2 是氢或低级烷基； 这些化合物是 LHRH 拮抗剂。这些化合物是 LHRH 拮抗剂。
• Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists, their preparation and compositions containing them
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0097031A2

  公开（公告）日：1983-12-28

  Nonapeptide and decapeptide analogs of LHRH which have the formula and the pharmaceutically acceptable salts thereof, wherein: A is an amino acyl residue selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, N-acyl-D,L-tryptophanyl, N-acyl-glycyl, N-Ac-D,L-Δ3,4-prolyl, N-Ac-D,L-prolyl, N-Ac-L-alkylprolyl, N-Ac-D,L-phenylalanyl, N-Ac-D,L-p-chlorophenylalanyl, N-Ac-D,L-seryl, N-Ac-D,L-threonyl, N-Ac-D,L-alanyl, 3-(1-naphthyl)-D,L-alanyl, 3-(2-naphthyl)-D,L-alanyl, 3-(2,4,6-trimethylphenyl)-D,L-alanyl, 3-(4-trifluoromethylphenyl)-D,L-alanyl, 3-(9-anthryl)-D,L-alanyl, 3-(2-fluorenyl)-D,L-alanyl, and 3-(Het)-D,L-alanyl wherein Het is a heterocyclic aryl containing radical selected from wherein A" and A' are independently selected from the group consisting of hydrogen, lower alkyl, chlorine and bromine, and G is selected from the group consisting of oxygen, nitrogen and sulfur; B is an amino acyl residue selected from the group consisting of D-phenylalanyl, D-p-Cl-phenylalanyl, D-p-F-phenylalanyl, D-p-nitrophenylalanyl, 3-(3,4,5-trimethoxyphenyl)-D-alanyl, 2,2-diphenylglycine, D-a-methyl-p-Cl-phenylalanine and 3-(2,4,6-trimethylphenyl)-D-alanyl; C is an amino acyl residue selected from the group consisting of L-tryptophanyl, D-tryptophanyl, D-phenylalanyl, D-Mesphenylalanyl, 3-(2-pyridyl)-D-alanyl, 3-(3-pyridyl)D-alanyl, 3-(1-naphthyl)-D-alanyl, 3-(2-naphthyl)-D-alanyl and 3-(4-pyridyl)-D-alanyl. D is an amino acyl residue selected from the group consisting of L-seryl, and D-alanyl; E is an amino acyl residue selected from the group consisting of L-phenylalanyl and L-tyrosyl; F is an amino acyl selected from the group consisting of the radicals represented by the following structural formulas: wherein n is 1 to 5 ; R, is alkyl of 1 to 12 carbon atoms, -NRR3 wherein R is hydrogen or alkyl of 1 to 4 carbon atoms, R3 is alkyl of 1 to 12 carbon atoms, cycloalkyl, phenyl, benzyl, -(CH2)n-morpholino or -(CH2)nN(R4)2 wherein n is 1 to 5 and R4 is lower alkyl; R2 is hydrogen or R3; or R, and R2 comprise a ring represented by the following structural formulas: wherein n is 1 to 7; A is hydrogen, alkyl of 1 to 6 carbon atoms or cycloalkyl; and X is halo or A or b) H2N-CH-CO2H wherein R5 is alkyl of 1 to 6 carbon atoms, benzyl, phenylethyl, cyclohexyl, cyclopentyl; and R6, R7 and R8 are hydrogen or alkyl of 1 to 4 carbon atoms; and n is the integer 2-5; or C) a substituent of the formula wherein R9 is hydrogen, alkyl of 1 to 12 carbon atoms, phenyl or phenylloweralkyl; G is an amino acyl residue selected from the group consisting of L-leucyl, L-norleucyl and L-norvatyl; H is D-alaninamide, D-leucinamide, glycinamide or -NHR5 wherein R5 is lower alkyl, cycloalkyl, fluoro lower alkyl, or NHCONH-R10 wherein R,o is hydrogen or lower alkyl; and the pharmaceutically acceptables salts thereof.

  LHRH 的非肽和十肽类似物，其分子式为 及其药学上可接受的盐类，其中 A 是一个氨基酰基残基，选自由 L-焦谷氨酰、D-焦谷氨酰、N-酰基-D,L-色氨酰、N-酰基-甘氨酰、N-Ac-D、L-Δ3,4-脯氨酰，N-Ac-D,L-脯氨酰，N-Ac-L-烷基脯氨酰，N-Ac-D,L-苯丙氨酰，N-Ac-D,L-氯苯丙氨酰，N-Ac-D,L-丝氨酰，N-Ac-D,L-苏氨酰、N-Ac-D,L-丙氨酰，3-(1-萘基)-D,L-丙氨酰，3-(2-萘基)-D,L-丙氨酰，3-(2,4,6-三甲基苯基)-D,L-丙氨酰，3-(4-三氟甲基苯基)-D,L-丙氨酰、3-(9-蒽基)-D,L-丙氨酰、3-(2-芴基)-D,L-丙氨酰和 3-(Het)-D,L-丙氨酰，其中 Het 是选自以下的含杂环芳基的基团 其中 A "和 A'独立地选自氢、低级烷基、氯和溴组成的组，G 选自氧、氮和硫组成的组； B 是氨基酰基残基，选自由 D-苯丙氨酰、D-对氯苯丙氨酰、D-对 F-苯丙氨酰、D-对硝基苯丙氨酰、3-(3,4,5-三甲氧基苯基)-D-丙氨酰、2,2-二苯基甘氨酸、D-a-甲基对氯苯丙氨酰和 3-(2,4,6-三甲基苯基)-D-丙氨酰组成的组； C 是氨基酰基残基，选自由 L-色氨酰、D-色氨酰、D-苯丙氨酰、D-甲苯丙氨酰、3-(2-吡啶基)-D-丙氨酰、3-(3-吡啶基)-D-丙氨酰、3-(1-萘基)-D-丙氨酰、3-(2-萘基)-D-丙氨酰和 3-(4-吡啶基)-D-丙氨酰组成的组。 D 是选自 L-丝氨酰和 D-丙氨酰的氨基酰基残基； E 是一个氨基酰基残基，选自由 L-苯丙氨酰和 L-酪氨酰组成的组； F 是一个氨基酰基，选自由下列结构式所代表的基团组成的组： 其中 n 为 1 至 5； R，是 1 至 12 个碳原子的烷基，-NRR3，其中 R 是氢或 1 至 4 个碳原子的烷基，R3 是 1 至 12 个碳原子的烷基、环烷基、苯基、苄基、-(CH2)n-吗啉基或-( )nN(R4)2，其中 n 是 1 至 5，R4 是低级烷基； R2 是氢或 R3；或 R 和 R2 由以下结构式代表的环组成： 其中 n 为 1 至 7；A 为氢、1 至 6 个碳原子的烷基或环烷基；X 为卤素或 A 或 b) H2N-CH-CO2H 其中 R5 是 1 至 6 个碳原子的烷基、苄基、苯乙基、环己基、环戊基；R6、R7 和 R8 是氢或 1 至 4 个碳原子的烷基；n 是 2 至 5 的整数；或 C) 式中的取代基 其中 R9 是氢、1 至 12 个碳原子的烷基、苯基或苯基低级烷基； G 是选自 L-亮氨酰，L-正亮氨酰和 L-正藜芦酰的氨基酰基残基； H 是 D-丙氨酰胺、D-亮氨酰胺、甘氨酰胺或-NHR5，其中 R5 是低级烷基、环烷基、氟低级烷基或 NHCONH-R10，其中 R,o 是氢或低级烷基；及其药学上可接受的盐。